Moreover, the potential for publication bias cannot be excluded, although the consistency of findings makes this less likely.As such, it is of most importance to consider studies with SGLT2 use in patients with chronic kidney disease and HF. Findings from studies evaluating the effects of SGLT2 (dapagliflozin [13] and empagliflozin [14]) inhibitors on chronic kidney disease and cardiovascular outcomes consistently demonstrate a reduced mortality risk among patients receiving SGLT2 inhibitors compared with placebo. The gene discussed is SLC5A2; the disease is chronic kidney disease.